Changzhou Qianhong Biopharma CO.,LTD (SHE:002550)
China · Delayed Price · Currency is CNY 7.84
+0.13 (1.69%)
Feb 3, 2026, 3:04 PM CST
SHE:002550 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,531 | 1,524 | 1,809 | 2,302 | 1,874 | 1,667 |
Other Revenue | 2.39 | 2.39 | 5.17 | 1.13 | 1.02 | 0.54 |
| 1,534 | 1,526 | 1,814 | 2,304 | 1,875 | 1,668 | |
Revenue Growth (YoY) | -1.43% | -15.88% | -21.24% | 22.86% | 12.43% | -0.45% |
Cost of Revenue | 654.81 | 696.31 | 1,045 | 1,419 | 1,045 | 880.42 |
Gross Profit | 878.84 | 829.94 | 768.81 | 884.31 | 829.44 | 787.19 |
Selling, General & Admin | 418.86 | 423.58 | 521.42 | 541.03 | 587.29 | 483.04 |
Research & Development | 113.39 | 104.45 | 97.08 | 88.31 | 71.18 | 69.14 |
Other Operating Expenses | 6.23 | 13.75 | 7.13 | 17.1 | 18.35 | 19.96 |
Operating Expenses | 511.26 | 547.81 | 606.62 | 661.74 | 677.06 | 577.18 |
Operating Income | 367.59 | 282.12 | 162.19 | 222.56 | 152.38 | 210.01 |
Interest Expense | -0.65 | -1.39 | -5.93 | -5.23 | -1.66 | -8.44 |
Interest & Investment Income | 27.25 | 21.49 | 19.3 | 5.64 | 1.6 | 21.61 |
Currency Exchange Gain (Loss) | 3.73 | 3.73 | 1.26 | 74.02 | -5.4 | -17.71 |
Other Non Operating Income (Expenses) | 80.29 | 84.85 | -1.83 | -0.02 | 52.55 | -378.37 |
EBT Excluding Unusual Items | 478.2 | 390.8 | 175 | 296.97 | 199.48 | -172.91 |
Gain (Loss) on Sale of Investments | 4.82 | 2.36 | 0.77 | -4.59 | 0.64 | 0.44 |
Gain (Loss) on Sale of Assets | -0.05 | - | 25.35 | 57.59 | - | - |
Asset Writedown | -0.09 | -0.04 | -7.77 | -0.24 | -0.46 | -1.6 |
Other Unusual Items | 3.06 | 2.72 | 10.18 | 10.6 | 9.72 | 4.95 |
Pretax Income | 485.94 | 395.84 | 203.52 | 360.33 | 209.38 | -169.12 |
Income Tax Expense | 83.22 | 62.66 | 24.85 | 40.42 | 23.04 | -21.49 |
Earnings From Continuing Operations | 402.72 | 333.18 | 178.67 | 319.91 | 186.34 | -147.63 |
Minority Interest in Earnings | 26.95 | 22.85 | 3.19 | 3.5 | -5.26 | 15.61 |
Net Income | 429.67 | 356.03 | 181.86 | 323.41 | 181.08 | -132.02 |
Net Income to Common | 429.67 | 356.03 | 181.86 | 323.41 | 181.08 | -132.02 |
Net Income Growth | 46.35% | 95.77% | -43.77% | 78.60% | - | - |
Shares Outstanding (Basic) | 1,269 | 1,272 | 1,299 | 1,294 | 1,207 | 1,200 |
Shares Outstanding (Diluted) | 1,269 | 1,272 | 1,299 | 1,294 | 1,207 | 1,200 |
Shares Change (YoY) | -0.89% | -2.11% | 0.41% | 7.16% | 0.58% | -4.01% |
EPS (Basic) | 0.34 | 0.28 | 0.14 | 0.25 | 0.15 | -0.11 |
EPS (Diluted) | 0.34 | 0.28 | 0.14 | 0.25 | 0.15 | -0.11 |
EPS Growth | 47.66% | 100.00% | -44.00% | 66.67% | - | - |
Free Cash Flow | 223.33 | 424.07 | 433 | -142.46 | 13.19 | 254.74 |
Free Cash Flow Per Share | 0.18 | 0.33 | 0.33 | -0.11 | 0.01 | 0.21 |
Dividend Per Share | 0.120 | 0.120 | 0.120 | 0.120 | 0.120 | 0.120 |
Dividend Growth | - | - | - | - | - | -52.00% |
Gross Margin | 57.30% | 54.38% | 42.38% | 38.39% | 44.24% | 47.21% |
Operating Margin | 23.97% | 18.48% | 8.94% | 9.66% | 8.13% | 12.59% |
Profit Margin | 28.02% | 23.33% | 10.02% | 14.04% | 9.66% | -7.92% |
Free Cash Flow Margin | 14.56% | 27.79% | 23.87% | -6.18% | 0.70% | 15.28% |
EBITDA | 428.74 | 346.73 | 231.41 | 287.33 | 221.82 | 280.26 |
EBITDA Margin | 27.96% | 22.72% | 12.75% | 12.47% | 11.83% | 16.81% |
D&A For EBITDA | 61.15 | 64.61 | 69.22 | 64.76 | 69.43 | 70.25 |
EBIT | 367.59 | 282.12 | 162.19 | 222.56 | 152.38 | 210.01 |
EBIT Margin | 23.97% | 18.48% | 8.94% | 9.66% | 8.13% | 12.59% |
Effective Tax Rate | 17.13% | 15.83% | 12.21% | 11.22% | 11.00% | - |
Revenue as Reported | 1,534 | 1,526 | 1,814 | 2,304 | 1,875 | 1,668 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.